![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Heller Simon Kurtzhals Peter Verge Danilo Lindholm Anders
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.3, Iss.2, 2002-02, pp. : 183-195
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Aspart
By Lindholm A.
Clinical Pharmacokinetics, Vol. 40, Iss. 9, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Drugs, Vol. 57, Iss. 5, 1999-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Insulin Aspart: A Viewpoint by Lutz Heinemann
By Heinemann L.
Drugs, Vol. 57, Iss. 5, 1999-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
`Endostatin' - first clinical results promising in cancer
Inpharma, Vol. 1, Iss. 1266, 2000-01 ,pp. :